Chronic Myelogenous Leukemia with e13a3 (b2a3) Type of BCR-ABL Transcript Having a DNA Breakpoint between ABL exons a2 and a3

American Journal of Hematology

Volumn 74, Issue 4, 2003, Pages 268-272

  Liu, Li Gen ^a,b   Tanaka, Hideo ^a   Ito, Kinro ^a   Kyo, Taiichi ^c   Ito, Takuo ^a   Kimura, Akiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Urology Institute of Fudan University   (China)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

ABL; BCR; Chronic myelogenous leukemia; DNA breakpoint

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB;

ADULT; ARTICLE; BCR ABL FUSION GENE; CANCER RESISTANCE; CASE REPORT; CELL ACTIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DNA STRAND BREAKAGE; EXON; FUSION GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; LABORATORY TEST; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; SPLENOMEGALY;

CHROMOSOME BREAKAGE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EXONS; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; INTRONS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; PHENOTYPE; RNA, MESSENGER; RNA, NEOPLASM; SPLENOMEGALY;

EID: 0344443802     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10429     Document Type: Article

References (16)

1. Melo JV. BCR-ABL gene variants. Baillière Clin Haematol 1997; 10:203-222.
2. van der Plas DC, Soekarman D, van Gent AM, Grosveld G, Hagemeijer A. bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogenous leukemia patient. Leukemia 1991;5:457-461.
3. Páldi-Haris P, Barta A, Lengyel L, et al. Molecular background of a new case of chronic myelogenous leukemia with bcr-abl chimera mRNA lacking the A2 exon. Leukemia 1994;8:1791.
4. Iwata S, Mizutani S, Nakazawa S, Yata J. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia 1994;8:1696-1702.
5. Polák J, Zemanová Z, Michalová K, Klamová H, Čermák J, Haškovec C. A new case of chronic myeloid leukemia (CML) in myeloid blast crisis with an atypical (b3/a3) junction of the BCR/ABL gene. Leukemia 1998;12:250.
6. Amabile M, Martinelli G, Terragna C, Montefusco V, Tabilio A, Tura S. An atypical (b3a3) junction of the bcr/abl gene lacking abl exon a2 in a patient with chronic myeloid leukemia. Haematologica 1999;84:573-575.
7. Martinelli G, Amabile M, Terragna C, et al. Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient. Leukemia 1999;13:1463-1464.
8. + chronic myeloid leukemia patients. Blood 2000;95:4019-4020.
9. Wilson GA, Vandenberghe EA, Pollitt RC, et al. Are aberrant BCR-ABL transcripts more common than previously thought? Br J Haematol 2000;111:1109-1111.
10. Roman J, Jimenez A, Barrios M, Castillejo JA, Maldonado J, Torres A. E1A3 as a unique, naturally occurring BCR-ABL transcript in an indolent case of chronic myeloid leukaemia. Br J Haematol 2001;114:635-637.
11. Al-Ali H-K, Leiblein S, Kovacs I, Henning E, Niederwieser D, Deininger MWN. CML with an ela3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall. Blood 2002;100:1092-1093.
12. Soekarman D, van Denderen J, Hoefsloot L, et al. A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 1990;4:397-403.
13. Jeffs AR, Wells E, Morris CM. Nonrandom distribution of interspersed repeat elements in the BCR and ABL1 genes and its relation to breakpoint cluster regions. Genes Chromosomes Cancer 2001;32:144-154.
14. Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood 1998;91:406-418.
15. Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999;189:1229-1242.
16. Gross AW, Zhang X, Ren R. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol 1999;19:6918-6928.